Intrathecal Pemetrexed for Leptomeningeal Metastasis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

March 20, 2023

Study Completion Date

March 31, 2024

Conditions
Leptomeningeal Metastases
Interventions
DRUG

Pemetrexed (1)

Pemetrexed (Alimta, Eli Lilly and Company) is administrated by intrathecal injection, plus dexamethasone, twice per week for 2 weeks, followed by once per week for 4 weeks. The initial dose of intrathecal pemetrexed is 15 mg, escalated to 20 mg, and then 25 mg....

DRUG

Pemetrexed (2)

The maximum-tolerated dose determined in phase I study is chosen as the treatment dose in phase II study.

DRUG

Folic Acid

Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.

DRUG

Vitamin B12

A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed, once per 3 weeks.

DRUG

Dexamethasone

Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.

Trial Locations (1)

130021

The First Hospital of Jilin University, Changchun

All Listed Sponsors
collaborator

Affiliated Hospital of Guangdong Medical University

OTHER

collaborator

Second Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Guangdong 999 Brain Hospital

OTHER

collaborator

The Second Hospital of Hebei Medical University

OTHER

collaborator

Panjin Liaoyou Gem Flower Hospital

UNKNOWN

collaborator

Wuxi People's Hospital

OTHER

collaborator

Huizhou Third People's Hospital, Guangzhou Medical University

OTHER

lead

The First Hospital of Jilin University

OTHER